ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024 Business Wire Mon, Mar 3, 2025, 7:30 AM 18 min read ...

For the first time since 2012, the Oklahoma City Thunder is in the NBA Finals. After the Thunder locked up a 128-126 thriller in Game 4 of the Western Conferenc ...

Robust franchise unit growth in the quarter fueled the outperformance, although a waning consumer appetite for restaurant spending tempers our 2025 outlook for comparable sales growth. Overall ...

ImmunityBio, Inc. ( NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its ...

It has already gained strong momentum in the automotive world ... BlackBerry’s QNX business, formed by rebranding its IoT unit, is gaining from strength in the automotive segment, particularly ...